ENTA vs. RLAY, OPT, ORIC, MNMD, MAZE, SION, VERV, SAGE, CGEM, and TRVI
Should you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include Relay Therapeutics (RLAY), Opthea (OPT), ORIC Pharmaceuticals (ORIC), Mind Medicine (MindMed) (MNMD), Maze Therapeutics (MAZE), Sionna Therapeutics (SION), Verve Therapeutics (VERV), Sage Therapeutics (SAGE), Cullinan Therapeutics (CGEM), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical products" industry.
Enanta Pharmaceuticals vs.
Enanta Pharmaceuticals (NASDAQ:ENTA) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, community ranking, media sentiment, profitability, institutional ownership, risk, dividends and earnings.
Enanta Pharmaceuticals has higher revenue and earnings than Relay Therapeutics. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.
Relay Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -157.57%. Relay Therapeutics' return on equity of -45.75% beat Enanta Pharmaceuticals' return on equity.
Enanta Pharmaceuticals has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.
Enanta Pharmaceuticals received 258 more outperform votes than Relay Therapeutics when rated by MarketBeat users. However, 70.45% of users gave Relay Therapeutics an outperform vote while only 56.94% of users gave Enanta Pharmaceuticals an outperform vote.
95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 13.9% of Enanta Pharmaceuticals shares are held by insiders. Comparatively, 4.3% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Enanta Pharmaceuticals presently has a consensus target price of $17.25, suggesting a potential upside of 202.10%. Relay Therapeutics has a consensus target price of $19.80, suggesting a potential upside of 627.94%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than Enanta Pharmaceuticals.
In the previous week, Relay Therapeutics had 3 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 5 mentions for Relay Therapeutics and 2 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.93 beat Relay Therapeutics' score of 0.83 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.
Summary
Relay Therapeutics beats Enanta Pharmaceuticals on 12 of the 19 factors compared between the two stocks.
Get Enanta Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enanta Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ENTA) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy ENTA Stock Free ENTA Stock Alerts